A new report by the Health and Human Services Department’s Office of Inspector General found that Medicare paid 80% more, on average, for Johnson & Johnson’s Stelara for the same conditions in 2021 when it was obtained under Part D instead of Part B.
Key Takeaways
-
Medicare and beneficiary costs for Stelara increased sharply after the drug was excluded from Part B coverage in 2021, but use shifted to Part D, the HHS Office of Inspector General concluded in a recent report.
The OIG also found that from 2016 through 2021, the average Part B cost of Stelara remained relatively steady, fluctuating...
